Results 61 to 70 of about 26,298 (212)

Heterogeneity Analyzed by CT‐Based Habitat Analysis for Clinical Management of Cancers: A Narrative Review

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Tumors are highly heterogeneous, and whole‐lesion radiomics analysis is a popular method for extracting texture features that reflect this heterogeneity, which can be used to build models for cancer diagnosis, staging, therapy response evaluation, and prognosis prediction.
Yang Zhang, Zhi‐Yan Jin, Min‐Ying Lydia Su   +2 more
wiley   +1 more source

C-KIT mutation in thymic carcinomas [PDF]

, 2020
Thymic epithelial tumours are rare malignancies of the anterior superior mediastinum. Several studies have analysed the presence of c-KIT mutations in thymic carcinoma. Immunohistochemical c-KIT expression and mutations in exons 8, 9, 11, 13, 14, 17, and
Evsen Arikan, Arikan, Evşen, Terzi, Neslihan Kaya, Ismail Yilmaz, ÖZ, Ayşim Büge, Neslihan Terzi, Yegen, Gulcin, Cansu Yol, Yilmaz, Ismail, BATUR, Şebnem, Yol, Cansu, Gulcin Yegen, Sebnem Batur, Aysim Oz   +13 more
core   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study [PDF]

, 2018
BACKGROUND: The prognostic factors and the efficacy of first-line chemotherapy remain unclear in patients with advanced thymic carcinoma. MATERIALS AND METHODS: We conducted a multi-institutional retrospective study named NEJ023 for patients with ...
Sugiyama, Tomohide, Ko, Ryo, Iwasawa, Shunichiro, Yamasaki, Masahiro, Okuma, Yusuke, Muraki, Keiko, Fujiwara, Akiko, Shukuya, Takehito, Imai, Hisao, Miyauchi, Eisaku, Tanaka, Hisashi, Takashima, Yuta, Tateishi, Kazunari, Azuma, Keisuke, et al.   +14 more
core   +1 more source

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression

Case Reports in Oncology, 2018
Thymic carcinoma is a relatively rare and aggressive thymic epithelial tumor. Herein, we report successful treatment of thymic carcinoma with pembrolizumab. A 68-year-old woman was admitted to our hospital for evaluation of chest pain.
Takuma Isshiki, Kazutoshi Isobe, Naobumi Tochigi, Motoko Sunakawa, Yasuhiko Nakamura, Kazutoshi Shibuya, Susumu Sakamoto, Yujiro Takai, Sakae Homma   +8 more
doaj   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

Muscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza, Mattia Schiavolin, Francesca Beretta, Sara Cornacchini, Antonio Lotti, Gregorio Spagni, Valentina Damato   +6 more
wiley   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Thymic Carcinoma with Brain Metastasis Mimicking Meningioma [PDF]

, 2002
Thymic carcinoma is a rare malignancy, which differs from thymoma in that it displays histopathologically malignant features, extensive local invasion, and a substantial potential for metastasis, predominantly to the liver and kidney and rarely to the ...
안정용
core   +1 more source

Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report

JTO Clinical and Research Reports
Introduction: Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein overexpressed in various cancer types. Although TROP2-targeting therapy is currently attracting attention, little is known about TROP2 expression in thymic carcinoma.
Kana Kurokawa, MD, PhD, Tetsuhiko Asao, MD, PhD, Takuo Hayashi, MD, PhD, Satsuki Kishikawa, MD, PhD, Koichiro Kanamori, MD, PhD, Takehito Shukuya, MD, PhD, Yosuke Miyashita, MD, Ikuko Nakamura, MD, PhD, Taichi Miyawaki, MD, PhD, Ryota Kanemaru, MD, PhD, Tomoyasu Mimori, MD, PhD, Yoichiro Mitsuishi, MD, PhD, Ken Tajima, MD, PhD, Naoko Shimada, MD, PhD, Fumiyuki Takahashi, MD, PhD, Kazuya Takamochi, MD, PhD, Kenji Suzuki, MD, PhD, Kazuhisa Takahashi, MD, PhD   +17 more
doaj   +1 more source

A spontaneous reduction in tumor size of a thymic carcinoma: a case report

Surgical Case Reports, 2022
Background Spontaneous regression of thymic carcinoma is extremely rare. We report a case of a resected thymic carcinoma with preoperative spontaneous regression in a 67-year-old woman.
Shoei Kuroki, Takanori Ayabe, Hiroyuki Tanaka, Hiroshi Nakada, Ryo Maeda   +4 more
doaj   +1 more source